study_id,year,design,effect_type,effect_point,ci_low,ci_high,n_treat,n_ctrl,risk_of_bias,doi,journal_id,outcome,population,adverse_events,duration_weeks
LONG-LON01_01,2018,randomized controlled trial,SMD,0.3852,0.186,0.5844,63,72,mixed,10.1234/nicotinamide-riboside-long-lon01-01,longevity_journal,cellular_ageing,Adults with cellular ageing concerns,None reported,10
LONG-LON01_02,2019,randomized controlled trial,SMD,0.2984,0.1461,0.4507,60,74,mixed,10.1234/nicotinamide-riboside-long-lon01-02,longevity_journal,cellular_ageing,Adults with cellular ageing concerns,None reported,8
LONG-LON01_03,2020,randomized controlled trial,SMD,0.3115,0.132,0.491,71,58,low,10.1234/nicotinamide-riboside-long-lon01-03,longevity_journal,cellular_ageing,Adults with cellular ageing concerns,None reported,9
